Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide LAR in rare pancreatic and duodenal neuroendocrine tumors
2008-007348-32Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2009
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pasireotide LAR in apudoma (NET), insulinoma, gastrinoma and 2 more, sponsored by Novartis. Primary endpoint: Biochemical tumor marker response at 6 months. Started Jun 2009; status: completed.
02
Drugs
pasireotide LAR
03
Conditions
apudoma (NET)insulinomagastrinomaPancreatic VIPoma (VIPoma)glucagonoma
Beyond the preview
Go deeper on 2008-007348-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007348-32.